Loo Ke-Yan, Letchumanan Vengadesh, Ser Hooi-Leng, Teoh Siew Li, Law Jodi Woan-Fei, Tan Loh Teng-Hern, Ab Mutalib Nurul-Syakima, Chan Kok-Gan, Lee Learn-Han
Novel Bacteria and Drug Discovery Research Group (NBDD), Microbiome and Bioresource Research Strength (MBRS), Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Malaysia.
School of Pharmacy, Monash University Malaysia, Bandar Sunway 47500, Malaysia.
Microorganisms. 2021 Mar 15;9(3):605. doi: 10.3390/microorganisms9030605.
People around the world ushered in the new year 2021 with a fear of COVID-19, as family members have lost their loved ones to the disease. Millions of people have been infected, and the livelihood of many has been jeopardized due to the pandemic. Pharmaceutical companies are racing against time to develop an effective vaccine to protect against COVID-19. Researchers have developed various types of candidate vaccines with the release of the genetic sequence of the SARS-CoV-2 virus in January. These include inactivated viral vaccines, protein subunit vaccines, mRNA vaccines, and recombinant viral vector vaccines. To date, several vaccines have been authorized for emergency use and they have been administered in countries across the globe. Meanwhile, there are also vaccine candidates in Phase III clinical trials awaiting results and approval from authorities. These candidates have shown positive results in the previous stages of the trials, whereby they could induce an immune response with minimal side effects in the participants. This review aims to discuss the different vaccine platforms and the clinical trials of the candidate vaccines.
世界各地的人们在对新冠病毒的恐惧中迎来了2021年新年,因为许多家庭成员因这种疾病失去了亲人。数百万人被感染,大流行危及了许多人的生计。制药公司正在争分夺秒地研发一种有效的新冠疫苗。随着1月份严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒基因序列的公布,研究人员开发了各种类型的候选疫苗。这些包括灭活病毒疫苗、蛋白亚单位疫苗、信使核糖核酸(mRNA)疫苗和重组病毒载体疫苗。迄今为止,几种疫苗已被批准紧急使用,并已在全球各国接种。与此同时,也有候选疫苗正在进行三期临床试验,等待当局的结果和批准。这些候选疫苗在试验的前期阶段已显示出积极结果,即在参与者中能以最小的副作用诱导免疫反应。本综述旨在讨论不同的疫苗平台以及候选疫苗的临床试验情况。